Evaxion Biotech AS (EVAX) - Net Assets
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has net assets worth $16.60 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.74 Million) and total liabilities ($13.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Evaxion Biotech AS to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.60 Million |
| % of Total Assets | 55.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | -123.47% |
| 10-Year Change | N/A |
| Growth Volatility | 189.45 |
Evaxion Biotech AS - Net Assets Trend (2017–2024)
This chart illustrates how Evaxion Biotech AS's net assets have evolved over time, based on quarterly financial data. Also explore Evaxion Biotech AS asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Evaxion Biotech AS (2017–2024)
The table below shows the annual net assets of Evaxion Biotech AS from 2017 to 2024. For live valuation and market cap data, see Evaxion Biotech AS market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.65 Million | +65.07% |
| 2023-12-31 | $-4.73 Million | -156.96% |
| 2022-12-31 | $8.30 Million | -74.40% |
| 2021-12-31 | $32.44 Million | +360.88% |
| 2020-12-31 | $7.04 Million | -24.82% |
| 2019-12-31 | $9.36 Million | +1105.59% |
| 2018-12-31 | $-931.00K | -136.51% |
| 2017-12-31 | $2.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evaxion Biotech AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11502568000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.52 Million | % |
| Other Comprehensive Income | $-3.60 Million | % |
| Other Components | $109.97 Million | % |
| Total Equity | $-1.65 Million | 100.00% |
Evaxion Biotech AS Competitors by Market Cap
The table below lists competitors of Evaxion Biotech AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Senetas Corporation Ltd
AU:SEN
|
$28.03 Million |
|
Imugene Ltd
AU:IMU
|
$28.04 Million |
|
Synergetic Auto Performance Public Company Limited
BK:ASAP
|
$28.06 Million |
|
Birman Wood and Hardware Ltd
TA:BIRM
|
$28.07 Million |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
$28.02 Million |
|
Hitron Systems
KO:019490
|
$28.02 Million |
|
Nova Wellness Group Bhd
KLSE:0201
|
$28.01 Million |
|
MegaMD Co. Ltd
KQ:133750
|
$28.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evaxion Biotech AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,729,000 to -1,652,000, a change of 3,077,000.
- Net loss of 10,567,000 reduced equity.
- New share issuances of 16,550,000 increased equity.
- Other comprehensive income decreased equity by 13,486,999.
- Other factors increased equity by 10,580,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.57 Million | -639.65% |
| Share Issuances | $16.55 Million | +1001.82% |
| Other Comprehensive Income | $-13.49 Million | -816.4% |
| Other Changes | $10.58 Million | +640.5% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Evaxion Biotech AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.16 | $4.50 | x |
| 2018-12-31 | $-1.94 | $4.50 | x |
| 2019-12-31 | $23.12 | $4.50 | x |
| 2020-12-31 | $17.38 | $4.50 | x |
| 2021-12-31 | $66.56 | $4.50 | x |
| 2022-12-31 | $14.05 | $4.50 | x |
| 2023-12-31 | $-6.92 | $4.50 | x |
| 2024-12-31 | $-1.54 | $4.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evaxion Biotech AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -316.00%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-98.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.44 Million |
| 2019 | -119.56% | 0.00% | 0.00x | 1.18x | $-12.13 Million |
| 2020 | -213.38% | 0.00% | 0.00x | 1.70x | $-15.72 Million |
| 2021 | -75.63% | 0.00% | 0.00x | 1.24x | $-27.78 Million |
| 2022 | -279.04% | 0.00% | 0.00x | 2.65x | $-24.00 Million |
| 2023 | 0.00% | -30308.22% | 0.01x | 0.00x | $-21.65 Million |
| 2024 | 0.00% | -316.00% | 0.27x | 0.00x | $-10.40 Million |
Industry Comparison
This section compares Evaxion Biotech AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evaxion Biotech AS (EVAX) | $16.60 Million | 0.00% | 0.79x | $28.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected mel… Read more